Supplementary materials.docx (234.73 kB)

Supplementary materials: Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.docx

dataset

posted on 2021-12-09, 09:19 authored by Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng

Table A1. Clinical Inputs.

Table A2. Cost Inputs.

Table A3: Resource utilization.

Table A4. Utility inputs.

Figure A1. Probabilistic sensitivity analysis scatterplot.

Funding

Funded by Takeda Pharmaceuticals International Co.

History

Usage metrics

Read the peer-reviewed publication

Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

Journal of Comparative Effectiveness Research

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

brentuximab cost-effectiveness cutaneous T-cell lymphoma vedotin Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports